Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3980715 | 0.90 | PTPN1 (0.44) | PTPN1PTPN2PTPN6ELANEBCL2 | |
| SCHEMBL4343854 | 0.85 | GABRA1 (0.52) | MEN1HTTGFERKMT2AHSD17B10 | |
| SCHEMBL4342474 | 0.82 | IAPP (0.41) | MEN1HTTGFERKMT2AHSD17B10 | |
| SCHEMBL4335272 | 0.81 | GABRA1 (0.54) | MEN1HTTGFERKMT2AHSD17B10 | |
| SCHEMBL6150721 | 0.80 | PTGER4 (0.44) | MEN1HTTGFERKMT2AHSD17B10 | |
| SCHEMBL20097500 | 0.80 | ALDH1A1 (0.52) | KMT2A | |
| SCHEMBL4332057 | 0.80 | IAPP (0.44) | BCL2L1ALOX5 | |
| SCHEMBL3953857 | 0.79 | AKR1B1 (0.48) | MEN1HTTGFERKMT2AHSD17B10 | |
| SCHEMBL4334985 | 0.78 | CA2 (0.42) | MEN1HTTGFERKMT2AHSD17B10 | |
| SCHEMBL4342982 | 0.78 | GABRA1 (0.42) | KMT2AELANEBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427770-B1 | PROCESS FOR THE PRODUCTION OF POLYCARBONATE | GEN ELECTRIC (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1427770-A1 | PROCESS FOR THE PRODUCTION OF POLYCARBONATE | GENERAL ELECTRIC COMPANY (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030120025-A1 | Process for the production of polycarbonate | GENERAL ELECTRIC COMPANY | 2003-06-26 | — | — | US | disclosed |
| WO-2003022905-A1 | PROCESS FOR THE PRODUCTION OF POLYCARBONATE | GENERAL ELECTRIC COMPANY (US) | 2003-03-20 | — | — | WO | disclosed |
| US-6525163-B1 | Reducing static charge, improving heat aging, and lowering water absorption by increasing endcap levels | GENERAL ELECTRIC COMPANY | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120025-A1 | Process for the production of polycarbonate | RNGTT, CAPG, RPL30 | MEN1 3941/4885HTT 2326/4885GFER 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.